One of the most enigmatic problems in rheumatology has been juvenile idiopathic arthritis (JIA). Firstly, the classification has often depended on clinical features that have variations between patients. Secondly, there are different classification schemes in usage and there are few objective serologic tests that help to resolve the differences between the criteria sets. Thirdly, only recently have significant advances been made in understanding the immunology and immunopathology of JIA and, in particular, new treatment options. In this review, we will define the historical basis of JIA and emphasize not only the clinical features, but also the immunological characteristics, the pathogenesis, and treatment options. We will also discuss, in particular, quality of life, psychosocial functioning, socioeconomic outcomes and the difficult area of mortality. Finally, this review will attempt to bridge genetic observations with clinical presentation. JIA represents a relatively common syndrome of pediatric onset rheumatologic disease and a better understanding of the clinical definition, the relationship to autoimmunity, and novel treatments with biologic agents are critical for improved patient care.

    Polls results

    On a scale of 1 to 10, rate how much this article will change your clinical practice?

    NO change
    BIG change
    70% Article relates to my practice (12/17)
    17% Article does not relate to my practice (3/17)
    11% Undecided (2/17)

    Will this article lead to more cost-effective healthcare?

    47% Yes (8/17)
    29% No (5/17)
    23% Undecided (4/17)

    Was this article biased? (commercial or personal)

    12% Yes (2/16)
    68% No (11/16)
    18% Undecided (3/16)

    What level of evidence do you think this article is?

    0% Level 1 (0/18)
    11% Level 2 (2/18)
    27% Level 3 (5/18)
    27% Level 4 (5/18)
    33% Level 5 (6/18)